

TH

<b>Notice of Allowability</b>	Application No.	Applicant(s)	
	10/035,216	CHIOCCA ET AL.	
	Examiner	Art Unit	
	Daniel M. Sullivan	1636	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the Paper filed 3 October 2006.
2. ☒ The allowed claim(s) is/are 40-45 and 47-57.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☐ All    b) ☐ Some\*    c) ☐ None    of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
  - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |   |  |
|---|--|
| <ol style="list-style-type: none"> <li>1. <input type="checkbox"/> Notice of References Cited (PTO-892)</li> <li>2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3. <input type="checkbox"/> Information Disclosure Statements (PTO/SB/08),<br/>Paper No./Mail Date _____</li> <li>4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br/>of Biological Material</li> </ol> | <ol style="list-style-type: none"> <li>5. <input type="checkbox"/> Notice of Informal Patent Application</li> <li>6. <input type="checkbox"/> Interview Summary (PTO-413),<br/>Paper No./Mail Date _____</li> <li>7. <input type="checkbox"/> Examiner's Amendment/Comment</li> <li>8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance</li> <li>9. <input type="checkbox"/> Other _____</li> </ol> |
|---|--|

### REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

Rejection of claims 40-45 and 47-56 under 35 U.S.C. 103(a) as being unpatentable over Kim *et al.* (1998) *Genome Res.* 8:404-412 in view of Wang *et al.* (1996) *J. Virol.* 70:8422-8430 as evidenced by Woodfield *et al.* (2000) *Nucl. Acids Res.* 28:3323-3331 and claims 40, 56 and 57 under 35 U.S.C. 103(a) as being unpatentable over Kim *et al.* (*supra*) in view of Wang *et al.* (*supra*) and further in view of Saeki *et al.* (1998) *Hum. Gene Ther.* 9:2787-2794 is **withdrawn**.

In the remarks filed 3 October 2006, Applicant contends, "The insert alone in the retrofitted BAC clones of Kim was approximately 140 kb. (See Kim, page 406, Figure 1). A person of skill in the art would have understood that the relatively lower transfection efficiencies mentioned in Kim were likely caused by the very large size of the BAC clones used in this reference as compared to the much smaller amplicon vector used in Wang." (Page 11, first full paragraph.) This argument is deemed persuasive in view of the teaching of Wang *et al.*, "Theoretically, insertion of non-viral sequences into mini-HSV-1 as a monomeric vector may reach the total size of the viral genome. In the case of pH300, the theoretical maximum insertion size of foreign DNA might be as large as 130 to 140 kb." (Page 8428, right column, sentence immediately preceding the heading, "**Effective in vivo delivery in tumors as a potential tool for gene therapy.**") Given that the total size of the BAC construct (insert plus vector) of Kim *et al.* would exceed even the largest estimate for the theoretical maximum insert size for the HSV amplicon vector of Wang *et al.*, one of ordinary skill in the art, working at the time the instant application was filed, would not have been motivated to substitute the amplicon vector of Wang *et al.* for the selectable marker gene construct used by Kim *et al.* in a method of retrofitting BAC

Art Unit: 1636

vectors, nor would one of ordinary skill in the art have had a reasonable expectation of success in combining the teachings.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 571-272-0779. The examiner can normally be reached on Monday through Friday 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) (<http://pair-direct.uspto.gov>) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to

Art Unit: 1636

midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days.

Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

A handwritten signature in black ink, appearing to read "D. Sullivan", with a stylized flourish at the end.

Daniel M. Sullivan, Ph.D.  
Primary Examiner  
Art Unit 1636